Posted On: 07/09/2016 1:33:54 PM
Post# of 72447
Don't know if this was posted:
Good post from Farrell
A preview of the results of Otezla versus Prurisol was suggested in the CTIX Dermatology review released today.
See pages 26 and 27
http://cellceutix.com/wp-content/uploads/2014...16-1-1.pdf
By Week 12, 46% of
patients receiving
200mg of Prurisol with
“moderate” psoriasis
achieved IGA 0/1
(equivalent to PASI 90,
which increasingly is
the new standard.
In contrast only 8.1% of the Otezla patients achieved a PASI 90 at the end of the study which ran for 32 weeks.
There are marked differences in the studies. The Otezla study included severe psoriasis patients and ran 32 weeks.The Prurisol study included mild to moderate patient and only ran for 12weeks.
It is obvious the studies are not equivalent and it is dishonest to suggest a head to head controlled study would yield the same results, but it does confirm CTIX's assertion the Prurisol 200mg study results were very good in moderate psoriasis.
GLTA Farrell
Good post from Farrell
A preview of the results of Otezla versus Prurisol was suggested in the CTIX Dermatology review released today.
See pages 26 and 27
http://cellceutix.com/wp-content/uploads/2014...16-1-1.pdf
By Week 12, 46% of
patients receiving
200mg of Prurisol with
“moderate” psoriasis
achieved IGA 0/1
(equivalent to PASI 90,
which increasingly is
the new standard.
In contrast only 8.1% of the Otezla patients achieved a PASI 90 at the end of the study which ran for 32 weeks.
There are marked differences in the studies. The Otezla study included severe psoriasis patients and ran 32 weeks.The Prurisol study included mild to moderate patient and only ran for 12weeks.
It is obvious the studies are not equivalent and it is dishonest to suggest a head to head controlled study would yield the same results, but it does confirm CTIX's assertion the Prurisol 200mg study results were very good in moderate psoriasis.
GLTA Farrell
(3)
(0)
